IndiaTickerLatest filing: GlaxoSmithKline Pharmaceuticals Ltd - 500660 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
ObservedCompany dossier
GlaxoSmithKline Pharmaceuticals
NSE:GLAXO · ISIN INE159A01016
- Close
- ₹2,626.4 29 Jul 2026
- Daily change
- N/A Exchange close
- Evidence state
- Building 0/0 checks
GlaxoSmithKline Pharmaceuticals
Overview
Evidence state
Coverage in progressCompany record at a glance
Latest reported period: 31 Dec 2024 · revenue ₹949.4 Cr · PAT ₹229.9 Cr.
Exchange XBRLLatest ownership: promoter group 75.00% and public 25.00% as of 30 Jun 2026.
Exchange XBRLMaterial events
Open timeline →What changed recently
Observed
Source filing GlaxoSmithKline Pharmaceuticals Ltd - 500660 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
BSE · exchange filing
Observed
Source filing GlaxoSmithKline Pharmaceuticals Ltd - 500660 - Board Meeting Intimation for Approve And Take On Record The Un-Audited Financial Results For The First Quarter Ended 30Th June 2026.
BSE · financial results
Observed
Source filing Analysts/Institutional Investor Meet/Con. Call Updates - GlaxoSmithKline Pharmaceuticals Limited
NSE · conference call
Observed
Source filing Certificate under SEBI (Depositories and Participants) Regulations, 2018 - GlaxoSmithKline Pharmaceuticals Limited
NSE · exchange filing
Reported financials
Full financials →31 Dec 2024
- Revenue from operations
- ₹949.4 Cr
- Profit after tax
- ₹229.9 Cr
- EPS
- ₹13.57
Observed NSE structured filing · Consolidated
Ownership
Full shareholding →30 Jun 2026
- Promoter group
- 75.00%
- Public
- 25.00%
- Employee trust
- 0.00%
Observed NSE shareholding XBRL